Perilla for Health & Longevity
Evidence Review created on 10/17/2026 using AI4L + evidence-mcp / Gemini 4 Argon
Also known as: Perilla frutescens, Shiso, Zi Su, Egoma, Korean Perilla, Beefsteak Plant, Perilla Seed Oil, Perilla Leaf Extract
Motivation
Perilla (shiso, egoma, or zi su) is an aromatic East Asian herb from the mint family whose seeds and leaves yield two distinct oral preparations. Cold-pressed seed oil is one of the richest plant sources of omega-3 fatty acids, whereas leaf extracts concentrate antioxidant plant compounds and aromatic oils that act on inflammation pathways.
For more than two thousand years, traditional Chinese, Japanese, and Korean culinary and medical practices have used the leaf and seed for seasonal respiratory and digestive complaints. Over the past three decades, clinical researchers have investigated whether concentrated seed oils and leaf extracts influence blood cholesterol, seasonal allergies, and age-related cognitive function in human trials.
Because seed oil and leaf extract differ in chemical composition, absorption, and target tissues, evaluating perilla for longevity requires separating fatty-acid activity from leaf antioxidant effects. This review examines the human clinical trials, safety profile, drug interactions, and practical dosing protocols for oral perilla preparations in health optimization and longevity.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
This section curates accessible expert overviews and peer-reviewed narrative reviews covering the phytochemistry, pharmacology, and clinical applications of Perilla frutescens.
-
Rosmarinic Acid Provides Natural Allergy Relief - John Colman
Summarizes how Perilla frutescens leaf extract standardized for rosmarinic acid and luteolin modulates seasonal allergic rhinoconjunctivitis (nasal and eye allergy inflammation) and immune signaling in human and animal studies.
-
Applications of Perilla frutescens Extracts in Clinical Practice - Adam et al., 2023
Provides a clinical narrative overview of human interventional studies evaluating Perilla frutescens seed oil and leaf extracts across lipid metabolism, cognitive aging, gastrointestinal symptoms, and airway allergy.
-
Perilla frutescens: A Rich Source of Pharmacological Active Compounds - Hou et al., 2022
Catalogues approximately 400 bioactive metabolites across perilla leaves, seeds, and stems, linking specific polyphenols, terpenoids, and fatty acids to their molecular targets and enzyme-inhibitory activities.
-
Phytochemical and phytopharmacological review of Perilla frutescens L. (Labiatae), a traditional edible-medicinal herb in China - Yu et al., 2017
Examines traditional pharmacopeial classifications of perilla leaf, stem, and seed alongside modern phytopharmacological data and preclinical toxicology for volatile chemotypes.
-
Perilla frutescens: A traditional medicine and food homologous plant - Wu et al., 2023
Reviews the two-millennium cultivation history, nutritional profile, and dual food-medicine regulatory framework of Perilla frutescens in East Asia.
No articles or podcast episodes on perilla were found from priority experts Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Lifespan.io, as their coverage focuses on marine omega-3s and better-known polyphenols.
Grokipedia
Provides a comprehensive reference overview of Perilla frutescens taxonomy, East Asian culinary and traditional medicinal uses, major essential-oil chemotypes, and distinction from unrelated ornamental mints.
Examine
Perilla benefits, dosage, and side effects
Summarizes Perilla frutescens seed oil omega-3 fatty acid composition, traditional leaf use for stomach discomfort, and graded human clinical trial outcomes for blood lipids and inflammatory markers.
ConsumerLab
No dedicated ConsumerLab article or product quality review for Perilla was found.
Systematic Reviews
This section lists peer-reviewed systematic reviews and meta-analyses evaluating the therapeutic efficacy, molecular mechanisms, and human adverse-event profile of Perilla frutescens preparations.
-
The Effects of Perilla frutescens Extracts on IgA Nephropathy: A Systematic Review and Meta-Analysis - Adam et al., 2023
Meta-analyzes five controlled rat studies showing Perilla frutescens extracts reduce proteinuria (excess urine protein) in immunoglobulin A (IgA, a mucosal antibody) nephropathy.
-
The Antiviral Potential of Perilla frutescens: Advances and Perspectives - Chen et al., 2024
Systematically reviews active antiviral constituents of Perilla frutescens, mapping viral replicase inhibition and host immune-modulating pathways across respiratory and systemic viruses.
-
Safety of medicinal and edible herbs from fruit sources for human consumption: A systematic review - Liu et al., 2024
Evaluates human adverse-event reports across 30 edible medicinal fruits, identifying gastrointestinal, allergic, and neuropsychiatric events linked to high-dose Perillae fructus (perilla seed).
-
Herbal medicines for the treatment of allergic rhinitis: a systematic review - Guo et al., 2007
Assesses double-blind randomized controlled trials (RCTs, studies randomly assigning participants to treatment or control) of herbal interventions for seasonal allergic rhinitis.
-
Health supplements for allergic rhinitis: A mixed-methods systematic review - Pellow et al., 2020
Synthesizes 48 RCTs and 10 observational studies of allergic rhinitis supplements, highlighting positive outcomes for Perilla frutescens combined with quercetin and vitamin D3.
Mechanism of Action
Perilla frutescens acts through two distinct biochemical fractions. Cold-pressed seed oil contains 54–64% alpha-linolenic acid (ALA, an essential plant omega-3 polyunsaturated fatty acid), which elongates via fatty acid desaturase 2 (FADS2, the rate-limiting delta-6 desaturase enzyme) and fatty acid desaturase 1 (FADS1, the delta-5 desaturase enzyme) into eicosapentaenoic acid (EPA, an anti-inflammatory omega-3 fatty acid) and docosahexaenoic acid (DHA, a structural neural omega-3 fatty acid). Membrane ALA and EPA competitively inhibit arachidonic acid metabolism by cyclooxygenase-2 (COX-2, an inducible prostaglandin enzyme) and 5-lipoxygenase (5-LOX, a leukotriene enzyme), lowering leukotriene B4 (LTB4, a neutrophil chemoattractant) and leukotriene C4 (LTC4, an airway-constricting mediator) while activating peroxisome proliferator-activated receptor-gamma (PPAR-γ, a lipid-regulating nuclear receptor).
Leaf extracts concentrate rosmarinic acid, luteolin, apigenin, vicenin-2, and monoterpenes (perillaldehyde). These polyphenols inhibit nuclear factor kappa B (NF-κB, an inflammatory transcription factor), suppress tumor necrosis factor-alpha (TNF-α, a pro-inflammatory cytokine), activate nuclear factor erythroid 2-related factor 2 (Nrf2, an antioxidant transcription factor), block mast-cell histamine release, and relax gut smooth muscle. Competing mechanistic hypotheses debate whether seed oil benefits require slow hepatic conversion to EPA and DHA (<5–10% in humans) or direct ALA signaling. In a human study co-authored by manufacturer Meiji Seika Kaisha (Baba et al., 2005), oral rosmarinic acid peaks in plasma at 0.5 hours (2.0 hours for methylated metabolites), undergoes conjugation via catechol-O-methyltransferase (COMT, a methylating enzyme), uridine diphosphate-glucuronosyltransferases (UGT, glucuronidating enzymes), and sulfotransferases (SULT, sulfating enzymes), and is ~75% excreted renally within 6 hours (half-life 1–2 hours).
Historical Context & Evolution
Perilla frutescens has been cultivated across East Asia for more than 2,000 years as a culinary herb and classic medicine. Early Chinese compendia, including the Han-dynasty Shennong Bencao Jing and the modern Chinese Pharmacopoeia, classify three distinct medicinal parts (Yu et al., 2017): Perillae Folium (Zi Su Ye, leaf) for respiratory symptoms and seafood-related digestive distress; Perillae Caulis (Zi Su Geng, stem) for nausea and abdominal distension; and Perillae Fructus (Zi Su Zi, seed) for cough and constipation. In Japan and Korea, shiso leaves garnish raw fish while pressed egoma seed oil serves as a culinary fat.
Longevity interest began in the 1980s and 1990s when Japanese researchers identified perilla seed oil as one of the richest terrestrial sources of ALA. Early rodent studies reported that replacing omega-6 vegetable oils with perilla oil extended survival, improved maze learning, and suppressed colonic tumors. Subsequent human trials refined these findings (Ezaki et al., 1999; Kamalashiran et al., 2019): while perilla preparations raised circulating ALA and EPA and lowered low-density lipoprotein (LDL, plaque-forming blood lipid) cholesterol (LDL-C), apolipoprotein B (ApoB, primary LDL protein), or oxidized LDL (Ox-LDL, damaged LDL) in select clinical trials, conversion to DHA proved modest and seed oil did not reverse dementia, shifting work toward leaf extracts (Baek et al., 2026, funded by manufacturer Borambio Co., Ltd.).
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no clinical endpoint or validated surrogate has been replicated in placebo-controlled trials of standalone perilla across multiple independent research groups without conflicting trial results.
Medium 🟩 🟩
Allergic Rhinoconjunctivitis and Asthma Symptom Relief ⭕️ Not Central to Health & Longevity
Although not a direct longevity endpoint, airway allergy control reduces respiratory inflammation. In a 21-day double-blind RCT co-authored by Meiji Seika Kaisha (Takano et al., 2004, n = 29), rosmarinic-acid Perilla frutescens leaf extract (50–200 mg/day) reduced nasal neutrophil and eosinophil influx, relieving itchy nose and watery eyes. In a 4-week asthma RCT (Okamoto et al., 2000, n = 14), seed oil suppressed leukocyte LTB4 and LTC4 and increased forced vital capacity (FVC, total exhaled lung volume) and forced expiratory volume in 1 second (FEV1, first-second exhaled volume).
Magnitude: Responder rates for itchy nose, watery eyes, itchy eyes, and total symptoms increased significantly versus placebo over 21 days (p < 0.05; p-value, probability the difference arose by chance) (Takano et al., 2004), and FVC and FEV1 increased significantly between groups over 4 weeks (p < 0.05); the available study abstracts report no numerical between-group difference figures (Okamoto et al., 2000).
Gastrointestinal Comfort, Bowel Regularity, and Gut Microbiota Modulation
Perilla leaf extract (300 mg/day, standardized to vicenin-2 and rosmarinic acid) exerts antispasmodic and prokinetic (gut-motility-promoting) effects on intestinal smooth muscle, while seed oil ALA remodels colonic microbiota. A 4-week double-blind RCT sponsored by Vital Solutions GmbH (Buchwald-Werner et al., 2014, n = 50) improved bloating, rumbling, and abdominal discomfort, reaching between-group significance in women. An independent 8-week RCT in female athletes (Kawamura et al., 2023, n = 36) showed 3–9 g/day perilla oil reduced constipation scores, increased butyrate-producing Lachnospiraceae, and lowered uremic toxin (kidney-cleared metabolic waste) indoxyl sulfate.
Magnitude: Bloating and abdominal discomfort subscore improved significantly versus placebo in women with a 95% confidence interval (CI, plausible range of the true effect) of 0.003 to 0.77 (p = 0.048) (Buchwald-Werner et al., 2014); constipation scores decreased between groups (p = 0.035) and Lachnospiraceae abundance rose with Cohen’s d (standardized effect size) of 1.2 (p = 0.007) (Kawamura et al., 2023).
Bone Mineral Density Preservation
Long-term intake of ALA-rich perilla seed oil inhibits osteoclast (bone-resorbing cell) activity while raising erythrocyte (red blood cell) omega-3 levels and antioxidant capacity. In a 12-month double-blind RCT in healthy adults (Matsuzaki et al., 2023, n = 52, mean age 54.2 years), 7.0 mL/day seed oil significantly increased calcaneal (heel bone) bone mineral density (BMD, bone mineral content per area) as percentage of the Young Adult Mean (%YAM, ultrasound density vs young adults) and lowered serum tartrate-resistant acid phosphatase 5b (TRACP-5b, an osteoclast enzyme) versus olive oil.
Magnitude: Calcaneal %YAM increased and serum TRACP-5b decreased significantly compared with 7.0 mL/day olive oil placebo after 12 months of 7.0 mL/day perilla seed oil (p < 0.05); the available study abstract reports no numerical between-group difference figures (Matsuzaki et al., 2023).
Knee Joint Pain and Functional Mobility Improvement
Standardized Perilla frutescens leaf extract suppresses synovial (joint-lining) prostaglandin and inflammatory cytokine signaling to relieve age-related joint discomfort and preserve mobility. In an 8-week randomized, double-blind, placebo-controlled trial co-authored by manufacturer SFC Bio Co., Ltd. (Kim et al., 2023, n = 80 adults with mild knee pain), 1,400 mg/day leaf extract (700 mg twice daily) significantly reduced visual analogue scale (VAS, a 0–100 mm pain rating scale) knee pain and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, a standardized joint pain, stiffness, and function questionnaire) scores versus placebo.
Magnitude: Over 8 weeks, 1,400 mg/day leaf extract reduced knee pain VAS scores by 12.8 mm more than placebo (-19.6 ± 10.9 vs -6.8 ± 10.5 mm, p < 0.001) and improved total WOMAC scores by 11.2 points more than placebo (-20.5 ± 14.7 vs -9.3 ± 16.5 points, p < 0.01) (Kim et al., 2023).
Low 🟩
Platelet Aggregation and Vascular Inflammation Attenuation ⚠️ Conflicted
In an 8-week smoker RCT (Lee et al., 2026), 4.8 g/day seed oil prolonged adenosine diphosphate (ADP, a platelet activator) closure time and lowered leukocyte inflammatory transcripts. Conversely, a 10-month elder trial (Ezaki et al., 1999) found no platelet aggregation change. Net reading: antiplatelet effects are inconsistent.
Magnitude: Significant between-group prolongation of collagen-induced ADP closure time (p = 0.045) and reductions in leukocyte TNF-α (p = 0.027) and T-box transcription factor 21 (TBX21, the T-helper 1 immune transcription factor; p = 0.022) messenger ribonucleic acid (mRNA, gene transcript) expression after 8 weeks of 4.8 g/day perilla oil versus placebo (Lee et al., 2026), whereas 3 g/day ALA for 10 months produced no significant change in platelet aggregation or prothrombin time (Ezaki et al., 1999).
Atherogenic Lipid Profile and LDL Oxidation Reduction ⚠️ Conflicted
Seed oil lowered LDL-C in dementia (Kamalashiran et al., 2019) and lowered LDL-C and ApoB in diabetic dyslipidemia (abnormal blood lipids) (Wang et al., 2019). Healthy-adult trials lowered only Ox-LDL (Hashimoto et al., 2020) or showed no change (Ezaki et al., 1999). Net reading: cholesterol lowering is inconsistent.
Magnitude: Six-month post-treatment serum LDL-C was 0.29 mmol/L lower (2.60 ± 0.57 vs 2.89 ± 0.76 mmol/L) and ApoB was 0.11 g/L lower (0.96 ± 0.23 vs 1.07 ± 0.30 g/L) with 3 g/day perilla oil than fish oil (p < 0.05) (Wang et al., 2019), 9 g/day leaf powder lowered Ox-LDL by 21.2 U/L more than placebo (-41.9 vs -20.7 U/L, p < 0.05) without changing serum LDL-C or total cholesterol in healthy adults (Hashimoto et al., 2020), and 4 g/day seed oil lowered total cholesterol and LDL-C versus placebo in dementia (no numerical figures in abstract) (Kamalashiran et al., 2019).
Cognitive Function and Executive Performance ⚠️ Conflicted
A 12-week RCT of purple leaf extract (500 mg/day, Baek et al., 2026, n = 100, Borambio-funded) improved early cognitive decline. However, 6-to-12-month seed oil RCTs (Kamalashiran et al., 2019; Hashimoto et al., 2021) found no effect. Net reading: leaf extract aids early decline, whereas seed oil shows no benefit.
Magnitude: Over 12 weeks, 500 mg/day leaf extract improved Korean Mini-Mental State Examination-2 (K-MMSE-2, a global cognitive test) total scores by 1.10 points more than placebo (+2.25 ± 1.09 vs +1.15 ± 1.67 points, p = 0.001) and reduced Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog, a memory battery) error scores by 4.10 points more than placebo (-6.36 ± 5.12 vs -2.26 ± 4.33 points, p = 0.001) (Baek et al., 2026), whereas seed oil showed no between-group difference (Kamalashiran et al., 2019).
Blood Pressure Regulation ⚠️ Conflicted
A 6-month leaf powder RCT (9 g/day, Hashimoto et al., 2020, n = 60 randomized, 30 analyzed for blood pressure) found no full-cohort change in systolic blood pressure (SBP, peak arterial pressure) or diastolic blood pressure (DBP, resting pressure). Only prehypertensives improved. Net reading: normotensive blood pressure is unchanged.
Magnitude: No significant full-cohort between-group difference in morning SBP (p = 0.662) or DBP (p = 0.272) over 6 months (n = 30 with complete home blood pressure data, 23 overall completers); morning SBP (p = 0.005) and nocturnal SBP (p = 0.016) decreased versus placebo only in the baseline SBP ≥ 120 mmHg subgroup (n = 13); no numerical mmHg difference was reported (Hashimoto et al., 2020).
Mood and Depressive Symptom Support ⚠️ Conflicted
In a pregnancy RCT (Harauma et al., 2023), perilla oil lowered postpartum depression only versus historical controls, not fish oil. One 12-month RCT (Hashimoto et al., 2020) improved depression and apathy across adults, whereas another (Hashimoto et al., 2021) found no effect. Net reading: mood benefits remain inconsistent.
Magnitude: Twelve-month 7 mL/day perilla oil improved Zung Self-Rating Depression Scale (SDS, a 20-item depression scale; p = 0.037 full cohort, p = 0.041 women) and apathy changes (p = 0.031) versus olive oil (n = 65 completers) (Hashimoto et al., 2020), postpartum Edinburgh Postnatal Depression Scale (EPDS, a 10-item depression questionnaire) scores ≥ 9 occurred in 12.0% versus 22.3% on fish oil (p = 0.059) and 21.6% in historical controls (p = 0.044) (Harauma et al., 2023), and a 12-month elderly RCT showed no difference (p = 0.100) (Hashimoto et al., 2021).
Speculative 🟨
Colonic Chemoprevention
Rat studies show perilla oil and hull extract reduce colonic aberrant crypt foci (ACF, precancerous mucosal lesions) by 66.46% (Chantana et al., 2023; Corpet & Taché, 2002). Standalone human trials are lacking.
IgA Nephropathy Renal Protection
A meta-analysis of five rat studies (Adam et al., 2023) found Perilla frutescens extracts reduced proteinuria and glomerular (kidney filter) cell overgrowth in IgA nephropathy models. No controlled human trials exist.
Direct Antiviral Activity
In-vitro assays (Tang et al., 2021; Chen et al., 2024) show perilla leaf extracts block viral replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, the pandemic respiratory coronavirus). Standalone human trials are lacking.
Benefit-Modifying Factors
- Genetic polymorphisms: Variants in FADS1 and FADS2 govern conversion of seed oil ALA into EPA and DHA, while COMT variants alter methylation rates of leaf rosmarinic acid (Baba et al., 2005).
- Baseline biomarker levels: Lipid and blood pressure improvements occur predominantly in individuals with elevated baseline LDL-C, triglycerides, or SBP ≥ 120 mmHg, whereas adults with normal baseline lipids and blood pressure show minimal change (Wang et al., 2019; Hashimoto et al., 2020).
- Sex-based differences: Estrogen upregulates endogenous ALA-to-EPA/DHA conversion, and a 4-week RCT of perilla leaf extract (300 mg/day) showed stronger between-group relief of bloating and abdominal discomfort in women than men (Buchwald-Werner et al., 2014).
- Pre-existing health conditions: Early subjective or mild cognitive impairment responds better to standardized purple perilla leaf extract (Baek et al., 2026) than established mild-to-moderate dementia responds to seed oil (Kamalashiran et al., 2019).
- Age-related considerations: Middle-aged and older adults (mean age 54.2 years) exhibit slower delta-6 desaturase activity and require 6–12 months of seed oil supplementation (7.0 mL/day) to remodel erythrocyte membranes and preserve calcaneal BMD (Matsuzaki et al., 2023).
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: double-blind randomized controlled trials of perilla seed oil and leaf extract report adverse-event rates comparable to placebo, and documented harms come from uncontrolled clinical series, case reports, and animal toxicology studies.
Medium 🟥 🟥
No risk reaches Medium: controlled human trials have not demonstrated a statistically significant excess of any specific adverse event over placebo, restricting documented clinical harms to single-group series and case reports.
Low 🟥
Immediate Seed and Leaf Allergic Reactions
Perilla seed oil-storage (oleosin) proteins can trigger immunoglobulin E (IgE, the allergy antibody) mast-cell degranulation, causing urticaria (hives), angioedema (tissue swelling), bronchospasm (airway constriction), or anaphylaxis (systemic allergic shock). Evidence comes from a 21-patient clinical series (Jeong et al., 2023) and case reports (Shin et al., 2009).
Magnitude: Anaphylaxis occurred in 28.6% of 21 children with clinical perilla seed allergy, with positive skin-prick tests in 15 of 15 tested children and seed-specific IgE in 85.7% (no control group) (Jeong et al., 2023).
Allergic Contact Dermatitis
Direct skin handling of fresh Perilla frutescens leaves or essential oils can provoke cell-mediated delayed hypersensitivity reactions driven by leaf-surface monoterpenes, principally perillaldehyde and perillalcohol. Evidence comes from occupational dermatology case series and patch-test investigations in workers handling shiso leaves (Kanzaki & Kimura, 1992).
Magnitude: Not quantified in available studies. Published evidence consists of occupational case reports and patch-test series without a comparison group or population denominator (Kanzaki & Kimura, 1992).
Mild Gastrointestinal Disturbances ⚠️ Conflicted
Pharmacovigilance reports (Liu et al., 2024) note nausea and diarrhea after high-dose Perillae fructus intake due to unabsorbed oil. Conversely, double-blind RCTs of leaf extract (Baek et al., 2026) and seed oil (Matsuzaki et al., 2023) found no excess adverse events versus placebo. Net reading: standard doses are well tolerated.
Magnitude: Seven serious adverse-event cases (predominantly gastrointestinal and allergic) were logged for high-dose Perillae fructus across pharmacovigilance databases (no control group) (Liu et al., 2024), whereas 12-week leaf extract had adverse events reported in 2 of 50 participants versus 3 of 50 on placebo (p > 0.05) (Baek et al., 2026) and 12-month seed oil showed no excess events (Matsuzaki et al., 2023).
Speculative 🟨
Pulmonary Toxicity from Perilla Ketone Chemotypes
Veterinary studies (Doster, 2010; Breeze et al., 1984) show lung cytochrome P450 (CYP, xenobiotic-metabolizing enzymes) bioactivation of perilla ketone causes atypical interstitial pneumonia (acute alveolar edema) in grazing animals. No human supplement cases exist.
High-Dose Perillaldehyde Hepatotoxicity and Genotoxicity
Rodent assays (Hobbs et al., 2016, co-authored by flavor industry groups) found weak liver deoxyribonucleic acid (DNA, genetic material) damage only at hepatotoxic perillaldehyde doses. Human trials show no hepatotoxicity.
Risk-Modifying Factors
- Genetic polymorphisms: Variation in hepatic and pulmonary CYP monooxygenases and phase II UGT/SULT conjugating enzymes may alter clearance of volatile monoterpenes and phenolic acids (Baba et al., 2005).
- Baseline biomarker levels: Elevated baseline perilla-seed-specific IgE or prolonged baseline platelet closure time increases the likelihood of immediate allergic hypersensitivity or additive bleeding tendency (Jeong et al., 2023; Lee et al., 2026).
- Sex-based differences: No consistent sex-based differences in adverse-event rates have been identified across controlled human trials of perilla seed oil or leaf extract (Baek et al., 2026; Matsuzaki et al., 2023).
- Pre-existing health conditions: Atopic (allergy-prone) predisposition—such as existing food allergies, allergic rhinitis, or atopic dermatitis—heightens the risk of IgE-mediated seed anaphylaxis, which frequently presents alongside sesame or tree-nut sensitization (Jeong et al., 2023).
- Age-related considerations: Pediatric patients show higher rates of severe IgE-mediated perilla seed anaphylaxis (Jeong et al., 2023), while older adults on polypharmacy face higher theoretical antiplatelet interaction risk (Lee et al., 2026).
Key Interactions & Contraindications
- Anticoagulant and antiplatelet drugs (warfarin, apixaban, clopidogrel): Monitor (theoretical) — perilla oil (4.8 g/day) prolonged collagen-ADP platelet closure time in a human RCT (Lee et al., 2026), potentially increasing bleeding risk; clinical protocols monitor coagulation and pause use 7–14 days pre-surgery.
- Cytochrome P450 3A4 (CYP3A4, a major drug-metabolizing liver enzyme) substrates (tacrolimus, midazolam, atorvastatin): Caution (theoretical) — rosmarinic acid shows predicted CYP3A4 inhibition in computational profiling (Parvin et al., 2025), though no human interaction trial exists; administration is typically separated by 2–3 hours.
- Over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs, pain relievers such as aspirin, ibuprofen, naproxen): Monitor (theoretical) — additive COX-2 and platelet inhibition with perilla seed oil (Lee et al., 2026) may increase mucosal bleeding risk; protocols monitor for easy bruising.
- Over-the-counter histamine-1 receptor (H1, allergy histamine receptor) antihistamines (cetirizine, loratadine, fexofenadine): Low-risk additive — leaf extract suppresses nasal neutrophil and eosinophil influx (Takano et al., 2004) and combines with allergy therapy without excess sedation (Marseglia et al., 2019).
- Omega-3 and antiplatelet supplements (fish oil, krill oil, Ginkgo biloba, garlic): Caution (theoretical) — combining perilla oil with marine omega-3s or antiplatelet botanicals may additively prolong bleeding time (Wang et al., 2019; Lee et al., 2026); total omega-3 intake is adjusted accordingly.
- Antihypertensive supplements (coenzyme Q10, aged garlic extract, hibiscus): Monitor (theoretical) — in prehypertensive adults (SBP ≥ 120 mmHg), leaf powder (9 g/day) lowered morning and nocturnal SBP (Hashimoto et al., 2020), creating potential additive blood-pressure reduction.
- Standardized Citrus reticulata (ponkan) or Anredera cordifolia leaf powders: Synergistic co-intervention — 12-month Sankyo-co-authored trials (Hashimoto et al., 2022; Hashimoto et al., 2022) show combining 1.47 mL/day perilla oil with 1.12 g/day ponkan or Anredera cordifolia powder improves cognitive scores beyond oil alone.
Populations who should avoid Perilla:
- Individuals with confirmed IgE-mediated perilla seed allergy (Jeong et al., 2023).
- Individuals with documented allergic contact dermatitis to perilla leaf monoterpenes such as perillaldehyde or perillalcohol (Kanzaki & Kimura, 1992).
- Individuals with liver, renal, cardiovascular, or gastrointestinal disease, pregnant or lactating women, or those taking antiplatelet or lipid-altering medications, matching clinical trial exclusions (NCT02609295; Baek et al., 2026).
Risk Mitigation Strategies
Doses, timings, and operational safeguards below reflect common practice unless a specific source is cited.
- Chemotype-verified aqueous or ethanolic extracts: Protocols use commercial leaf extracts standardized for rosmarinic acid (such as Benegut at 300 mg/day, Buchwald-Werner et al., 2014) and verified free of pulmonary-toxic furylketones (perilla ketone and egomaketone, Doster, 2010).
- Split mealtime dosing for seed oil: Daily seed oil intake (3.0–7.0 mL/day, Wang et al., 2019; Matsuzaki et al., 2023) is divided into 2–3 doses with meals to prevent osmotic diarrhea, nausea, and upper gastrointestinal discomfort.
- Allergy evaluation in atopic individuals: Clinical allergy history and specialist evaluation precede initiating perilla seed products in individuals with sesame, tree-nut, or botanical seed anaphylaxis, as no standardized commercial perilla allergy test exists (Jeong et al., 2023).
- Perioperative and clotting pause: Protocols pause perilla seed oil 7–14 days before elective surgery or dental procedures and evaluate easy bruising to mitigate prolonged platelet closure time (Lee et al., 2026).
- Cold storage and peroxide control: Cold-pressed perilla seed oil is stored in dark airtight glass at 4 °C and discarded within 60–90 days of opening to prevent lipid peroxidation of its >54% polyunsaturated ALA content.
Therapeutic Protocol
Timing, splitting, and titration parameters without a citation reflect common clinical practice.
- Seed oil protocol: 3.0 g/day for diabetic dyslipidemia (Wang et al., 2019), 4.0 g/day in dementia (Kamalashiran et al., 2019), 4.8 g/day for platelets (Lee et al., 2026), or 7.0 mL/day for BMD (Matsuzaki et al., 2023).
- Leaf extract protocol: 1,400 mg/day for knee pain (Kim et al., 2023), 500 mg/day for cognition (Baek et al., 2026), 300 mg/day for gut (Buchwald-Werner et al., 2014), or 50–200 mg/day for allergy (Takano et al., 2004).
- Whole-leaf powder alternative: 9.0 g/day dried Perilla frutescens leaf powder lowered plasma Ox-LDL and prehypertensive SBP over 6 months in clinical research led by Michio Hashimoto’s group (Hashimoto et al., 2020).
- Time of day: Perilla seed oil is taken with fat-containing morning and evening meals to aid bile-salt emulsification; leaf extract is administered 30–60 minutes before breakfast and dinner for gastrointestinal symptoms (Buchwald-Werner et al., 2014).
- Expected human half-life: Oral rosmarinic acid peaks at 0.5 hours (2.0 hours for methylated metabolites) with ~75% renal elimination within 6 hours (effective half-life 1–2 hours, Baba et al., 2005); seed oil ALA equilibrates into erythrocyte membranes over weeks.
- Single versus split dosing: Aqueous leaf extracts are split into twice-daily doses (e.g., 150 mg twice daily, Buchwald-Werner et al., 2014) to offset rapid 6-hour phenolic clearance; seed oil may be taken once or split twice daily (1.5–3.5 g/dose).
- Genetic polymorphisms: Individuals with low-converting FADS1/FADS2 haplotypes may pair perilla seed oil with preformed marine DHA, while rapid COMT methylators benefit from twice-daily split leaf-extract dosing (Baba et al., 2005).
- Sex-based differences: Women demonstrated larger reductions in bloating and abdominal discomfort at 300 mg/day leaf extract (Buchwald-Werner et al., 2014), while female athletes needed 3–9 g/day seed oil for gut-microbiota and constipation improvements (Kawamura et al., 2023).
- Age-related considerations: Older adults (≥ 60 years) require sustained 6-to-12-month seed oil regimens (7.0 mL/day) to remodel erythrocyte phospholipid membranes and slow age-related bone resorption (Matsuzaki et al., 2023; Hashimoto et al., 2021).
- Baseline biomarker levels: Protocols use 3–7 mL/day seed oil when baseline LDL-C, ApoB, or TRACP-5b is elevated (Wang et al., 2019) and 9 g/day leaf powder when baseline SBP is ≥ 120 mmHg (Hashimoto et al., 2020).
- Pre-existing health conditions: In diabetic dyslipidemia, 3 g/day seed oil preferentially lowers LDL-C and ApoB whereas fish oil lowers triglycerides more (Wang et al., 2019); early cognitive decline protocols use 500 mg/day leaf extract (Baek et al., 2026).
Discontinuation & Cycling
- Lifelong versus short-term use: Seed oil for lipid and bone maintenance is used continuously over 6–12+ months (Matsuzaki et al., 2023), whereas leaf extract for seasonal allergies or gut discomfort is used for 3–12 weeks (Takano et al., 2004).
- Withdrawal effects: No physiological withdrawal syndrome, rebound hypertension, or rebound hyperlipidemia has been reported after stopping perilla seed oil or leaf extract in human clinical trials (Baek et al., 2026; Buchwald-Werner et al., 2014).
- Tapering-off protocol: No dose tapering is required; erythrocyte membrane ALA and EPA proportions gradually return toward baseline over 4–8 weeks of cell turnover after stopping seed oil.
- Cycling for efficacy: Continuous daily administration is used for cardiometabolic and skeletal goals without receptor desensitization, whereas allergy protocols cycle seasonally (starting 1–2 weeks before pollen exposure for 3–8 weeks, Takano et al., 2004).
Sourcing and Quality
- Formulation and chemotype specificity: Quality sourcing distinguishes cold-pressed Perilla frutescens seed oil (54–64% ALA, negligible rosmarinic acid) from aqueous/ethanolic leaf extracts (standardized to ≥ 2–3% rosmarinic acid, luteolin, and vicenin-2), avoiding uncharacterized essential oils from perilla-ketone (PK) chemotypes (Yu et al., 2017).
- Quality and oxidation markers to verify: Seed oil quality criteria include cold-pressed nitrogen-flushed bottling, dark glass or opaque softgels, added mixed tocopherols, and a Certificate of Analysis confirming low peroxide (< 5 mEq/kg) and anisidine values plus heavy-metal and pesticide testing.
- Clinically studied standardized ingredients: Human RCTs have tested standardized leaf extracts including Benegut (Vital Solutions GmbH, 300 mg/day standardized to vicenin-2 and rosmarinic acid, Buchwald-Werner et al., 2014) and Meiji Seika Kaisha rosmarinic-acid leaf extract (Takano et al., 2004).
Practical Considerations
- Time to effect: Allergic rhinoconjunctivitis and bloating improve within 3–28 days of leaf extract (Takano et al., 2004; Buchwald-Werner et al., 2014), cognitive scores shift by 12 weeks (Baek et al., 2026), and lipid or bone changes take 6–12 months (Matsuzaki et al., 2023).
- Common pitfalls: Using seed oil interchangeably with polyphenol leaf extract, cooking with unrefined perilla seed oil above its low smoke point (~160–180 °C, which oxidizes ALA into toxic aldehydes), or assuming plant ALA fully replaces marine DHA.
- Regulatory status: Dried leaf, stem, and seed are official medicine-and-food items in the Chinese Pharmacopoeia (Wu et al., 2023), while perillaldehyde was evaluated as a food flavoring by the European Food Safety Authority (EFSA, European food safety regulator) (Hobbs et al., 2016).
- Cost and accessibility: Both cold-pressed culinary egoma/perilla seed oil and encapsulated leaf extracts are widely accessible and inexpensive ($15–$35 per month), posing no exceptional financial or access barrier.
Interaction with Foundational Habits
- Sleep: Indirect potentiating interaction — neither seed oil nor leaf extract is sedating, but reducing nocturnal nasal congestion in allergic rhinitis (Takano et al., 2004) and lowering nocturnal SBP in prehypertensive adults (Hashimoto et al., 2020) can indirectly support sleep continuity when taken with dinner.
- Nutrition: Direct modifying interaction — high dietary linoleic acid (omega-6 vegetable oils) competes with perilla ALA for FADS2/FADS1 desaturase enzymes; lowering dietary omega-6 intake and pairing seed oil with fat-soluble antioxidants or citrus polyphenols (such as ponkan powder, Hashimoto et al., 2022) potentiates tissue omega-3 incorporation.
- Exercise: Direct potentiating interaction — in female athletes undergoing regular training, an 8-week RCT (Kawamura et al., 2023) showed 3–9 g/day perilla seed oil increased butyrate-producing Lachnospiraceae, reduced uremic indoxyl sulfate, and improved bowel regularity without blunting training adaptations.
- Stress management: Indirect potentiating interaction — 12 months of perilla seed oil supplementation reduced serum norepinephrine (a sympathetic stress catecholamine) alongside improved apathy and depressive symptom scores in healthy Japanese adults (Hashimoto et al., 2020).
Monitoring Protocol & Defining Success
Before oral perilla supplementation is initiated, baseline fasted laboratory blood testing establishes individual reference points for plaque-forming blood lipoproteins, red blood cell membrane omega-3 fatty acid proportions, osteoclast bone-resorption markers, and platelet closure time, while specialist allergy evaluation screens individuals with a personal or family history of sesame, tree-nut, or botanical seed anaphylaxis. During supplementation, fasted blood panels are re-evaluated at 4 weeks to verify early clinical tolerability and gastrointestinal comfort, at 8–12 weeks to confirm red blood cell membrane fatty-acid incorporation, lipid response, and hemostatic clotting safety, and every 6–12 months thereafter during ongoing cardiometabolic or skeletal preservation protocols to confirm sustained biomarker response and long-term safety.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Serum LDL-C and ApoB | No established target; track reduction from individual baseline | Efficacy marker: perilla seed oil (3 g/day) significantly lowers LDL-C and ApoB (Wang et al., 2019). | Drawn after a 9–12 hour overnight fast at baseline, 12 weeks, and 6 months. |
| Erythrocyte ALA and EPA (%) | No established target; track increase from individual baseline | Efficacy marker: confirms absorption and elongation of seed oil ALA (Lee et al., 2026). | Measured via red blood cell membrane fatty acid gas chromatography at baseline and 8–12 weeks. |
| Serum TRACP-5b | 170–590 mU/dL in men; 120–420 mU/dL in premenopausal women; 250–760 mU/dL in postmenopausal women (standard reference range) | Efficacy marker: 12-month seed oil intake lowers bone resorption (Matsuzaki et al., 2023). | Collected as morning fasted serum and paired with annual calcaneal ultrasound bone densitometry (%YAM). |
| Collagen-ADP Closure Time (PFA-100) | 62–100 seconds (standard reference range) | Safety and efficacy check: 4.8 g/day seed oil prolongs closure time (Lee et al., 2026). | Assessed at baseline and 8 weeks if co-administered with antiplatelet or anticoagulant agents; PFA-100 is Platelet Function Analyzer-100. |
| Perilla Seed Allergy Testing | No established target; qualitative absence of sensitization | Safety check: rules out IgE sensitization before use in seed-allergic individuals. | No commercial standardized assay or cutoff exists; custom seed-extract testing is restricted to specialist allergy workups (Jeong et al., 2023). |
Qualitative markers tracked during supplementation include:
- Bloating and stool regularity: Weekly digestive logs (Buchwald-Werner et al., 2014).
- Nasal and ocular symptoms: Daily allergy scores (Takano et al., 2004).
- Easy bruising: Ongoing bleeding-tendency check (Lee et al., 2026).
Emerging Research
- Functional dyspepsia trial (NCT07655219): An open-label RCT (n = 400, not yet recruiting, estimated completion November 2026) tests a ginger-and-perilla nutraceutical (Dispepril) alone or with half-dose proton pump inhibitor (PPI, acid suppressor) versus full-dose PPI over 14 days; positive findings would support PPI-sparing protocols, whereas null results would weaken dyspepsia claims.
- Acute overfeeding crossover study (NCT05603416): A triple-blind crossover RCT (n = 30, registered completion passed April 2023, status unknown, no results posted) evaluated Benegut perilla extract after acute overfeeding; positive results would extend chronic 4-week bloating benefits (Buchwald-Werner et al., 2014) to single-meal relief, while null results would limit acute use.
- Hypercholesterolemic hemostasis trial (NCT02609295): A Phase 3 RCT (n = 86, completed August 2015, no results posted) tested 1.2 g/day perilla oil versus medium-chain triglyceride (MCT, rapidly absorbed fat) oil on closure time; positive results would confirm antiplatelet effects below 4.8 g/day (Lee et al., 2026), while null results would indicate a higher threshold.
- Colonic delivery for appetite (NCT07448519): A quadruple-blind crossover RCT (n = 20 with obesity, completed August 2023) tested colonic capsules combining 3,3’-diindolylmethane (DIM, a cruciferous indole metabolite) and perilla oil; the registry reports increased peptide YY (PYY, a satiety hormone) and glucagon-like peptide-1 (GLP-1, an incretin hormone) plus lower female lunch intake versus placebo.
- Human translation of renal and cognitive findings: Rodent meta-analyses show proteinuria reductions in IgA nephropathy (Adam et al., 2023) and 12-week leaf extract improved early cognitive scores (Baek et al., 2026), whereas null 6-month dementia results with seed oil (Kamalashiran et al., 2019) highlight the need for head-to-head trials.
Conclusion
Perilla provides two distinct oral preparations with different biological profiles: cold-pressed seed oil rich in plant omega-3 fatty acids and leaf extracts concentrated in antioxidant plant compounds and aromatic oils. Across human randomized trials, moderate evidence supports leaf extract and seed oil for relieving seasonal nasal and eye allergy symptoms, easing abdominal bloating and constipation, reducing mild knee joint pain, and preserving heel bone density.
Evidence for cholesterol lowering, cognitive protection, blood pressure reduction, mood support, and blood-clotting modulation remains conflicted. Seed oil lowered harmful cholesterol in diabetes with abnormal blood lipids and in dementia, while leaf powder lowered oxidized cholesterol in healthy adults without altering standard cholesterol levels. Concentrated purple leaf extract improved test scores in early memory decline, whereas longer seed oil trials showed no standalone benefit in dementia or healthy aging. Similarly, blood pressure reductions appeared only in a borderline-high subgroup, mood improvements did not separate from fish oil, and blood-clotting and white-blood-cell inflammation markers improved in smokers but not in older adults. Key positive trials on digestive comfort, allergy, knee pain, cognition, and flavoring safety also involve manufacturer or industry co-authorship.
At studied doses, both oral preparations show placebo-like adverse-event rates in randomized trials, though documented risks include severe whole-body allergic reactions to perilla seed proteins, skin rashes from handling fresh leaves, and mild digestive upset at high oil intakes, alongside animal lung injury from wild plants high in toxic aromatic compounds.